Improving T-cell Therapy for Cancer Patients
Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy
This research aims to make T-cell therapies, like CAR T-cell therapy, work better and last longer for more cancer patients by strengthening their disease-fighting cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-11127643 on NIH RePORTER |
What this research studies
While T-cell therapies have shown great promise for some cancers, many patients do not respond or experience a relapse, especially those with solid tumors. The main challenges include T-cells not growing enough, not lasting long enough, failing to reach the tumor, or losing their ability to fight the cancer. Our team is exploring how to create more powerful "polyfunctional" CD4 T-cells, which are associated with better treatment outcomes. We are focusing on a specific cellular signal called STAT5, which can reprogram T-cells to be more effective and persistent against cancer. The ultimate goal is to develop enhanced T-cells that can overcome current treatment limitations and provide more successful outcomes for patients.
Who could benefit from this research
Good fit: Patients with various cancers, particularly those where current T-cell therapies are not fully effective or where solid tumors are present, could eventually benefit from this research.
Not a fit: Patients whose cancers are not targeted by T-cell therapies or who cannot undergo such treatments may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to more effective and durable T-cell therapies for a wider range of cancers, potentially offering new hope for patients who currently do not benefit from these treatments.
How similar studies have performed: Existing adoptive T-cell therapies have achieved significant success in certain blood cancers, and this research builds upon that foundation by exploring novel methods to enhance their effectiveness and broaden their application.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Zhou, Gang — Augusta University
- Study coordinator: Zhou, Gang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.